BioTuesdays

Category - Markets

Bionomics
Markets

Roth starts Bionomics at buy

Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday.“We believe a significant disconnect exists on the...

February 3, 2016
Carbylan Therapeutics
Markets

Leerink downgrades Carbylan to market perform

Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for...

February 2, 2016
EyeGate Pharmaceuticals
Markets

Rodman starts EyeGate Pharma at buy

Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437...

February 1, 2016
Volition
Markets

Rodman starts VolitionRx at buy

Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening...

February 1, 2016
BioBlast Pharma
Markets

Rodman starts BioBlast Pharma at buy

Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on platform-based solutions...

January 28, 2016
Seres Therapeutics Logo
Markets

HCW starts Seres Therapeutics at buy

QH.C. Wainwright has initiated coverage of Seres Therapeutics (NASDAQ:MCRB) with a “buy” rating and $55 price target. The stock closed at $24.88 on Friday. Seres is developing restorative microbial treatments that aim...

January 25, 2016
InspireMD
Markets

Rodman starts InspireMD at buy

Rodman & Renshaw has initiated coverage of InspireMD (NYSE MKT:NSPR) with a “buy” rating and 12-month price target of $4. The stock closed at 71 cents on Thursday. InspireMD is a commercial-stage company focusing on...

January 8, 2016
Avivagen
DevelopmentsMarkets

Avivagen issues letter to shareholders

In a letter to shareholders, Cameron Groome, CEO of Avivagen (TSX-V:VIV), provided and update about the company and its business plans. Mr. Groome said Avivagen continues the process of commercializing its non...

January 8, 2016
Accelerate Diagnostics
Markets

WB starts Accelerate Diagnostics at outperform

William Blair has launched coverage of Accelerate Diagnostics (NASDAQ:AXDX) with an “outperform” rating and an “aggressive growth” company profile. The stock closed at $19.97 on Thursday. Analyst Brian Weinstein writes...

January 8, 2016
Codexis
Markets

HCW starts Codexis at buy

H.C. Wainwright has launched coverage of Codexis (NASDAQ:CDXS) with a “buy” rating and $6 price target. The stock closed at $4.23 on Tuesday. Codexis is a biotechnology services company that specializes in the...

January 6, 2016